The rates of adverse events ( AEs ) and serious adverse events ( SAEs ) per 100 patient-months of followup were not higher in the triptorelin group compared with the placebo group ( for AEs , 189 versus 362 ; for SAEs , 2.1 versus 8.5 ) .